Fig 2: Self-Assembled X-polymer Nanoparticles and Verification of Their Binding to Target Proteins(A) Biotin-labeled 3WJ-2Del60 was assembled with Del60, Del60-3WJ, and T-p at the ratio of 1:4:1:1 (3WJ-2Del60:Del60:Del60-3WJ:T-p) and then identified by 10% native PAGE gel. (B) Biotin-labeled TRS was assembled with other components in X-polymer at the ratio of 1:4:1:1:1 (TRS:Del60:3WJ-2Del60:Del60-3WJ:T-p) and then identified by 10% native PAGE gel. (C) Self-assembled X-polymer nanoparticles with biotin-labeled TRS were identified to bind to CD28 and CTLA-4 in 8% native PAGE gel. The negative control target protein was TIM3.

Fig 3: Verification of the Binding of Aptamers to Their Target ProteinsAptamers were modified with a 3′-terminal biotin modification kit, incubated with the target proteins in EP tube and analyzed by 8% or 10% native PAGE gel. (A and C) The binding of CD28Apt7 to CD28 protein (A) and Del60 to CTLA-4 protein (C). The more protein added, the more obvious the binding band was. BSA or TIM3 were used as the negative control target proteins. (B and D) The cold competitive binding results of the aptamers to CD28protein (B) and CTLA-4 protein (D), respectively. The biotin unlabeled aptamer was used to compete the biotin labeled aptamer to the same target protein. (E and F) The binding (E) and cold competitive binding (F) of the dimer of CD28Apt7 to CD28 proteins.

Fig 4: PK profiling of mAbs. In vivo PK profiles from (a) a single-dose study and (b) a multiple-dose study of anti-mouse PD-L1 clone 80 mIgG1 D265A, anti-mouse PD-L1 clone 10 F.9G2, and anti-mouse mIgG1 CTLA-4. Measured serum mAb concentrations are indicated on the y-axis